TGTX: TG Therapeutics, Inc. Stock

by  •  • Comments Off on TGTX: TG Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 4,182.15
Enterprise Value ($M) 4,230.87
Book Value ($M) 177.57
Book Value / Share 1.24
Price / Book 23.55
NCAV ($M) 180.21
NCAV / Share 1.26
Price / NCAV 23.21

Profitability (mra)
Return on Invested Capital (ROIC) -0.03
Return on Assets (ROA) -0.04
Return on Equity (ROE) -0.09

Liquidity (mrq)
Quick Ratio 3.91
Current Ratio 4.59

Balance Sheet (mrq) ($M)
Current Assets 574.07
Assets 586.01
Liabilities 393.86
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Darwin Global Management, Ltd. 0.00 -100.00
10-07 13G/A BlackRock, Inc. 14.20
02-13 13G/A Vanguard Group Inc 9.03 -11.82
01-25 13G/A State Street Corp 5.45 -20.75

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-09 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. ☐ TRANSITION REP
2024-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. ☐ TRANSITION REPORT PURSUANT TO SECT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-17 457,904 1,769,714 25.87
2025-01-16 373,716 1,415,867 26.39
2025-01-15 583,573 2,420,897 24.11
2025-01-14 1,470,370 4,887,415 30.08

(click for more detail)

Similar Companies
TCRT – Alaunos Therapeutics, Inc. TELO – Telomir Pharmaceuticals, Inc.
TENX – Tenax Therapeutics, Inc. THAR – Tharimmune, Inc.
THTX – Theratechnologies Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: TG Therapeutics